At a glance
- Originator Bristol-Myers Squibb
- Class Antiplatelets
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 08 Jul 2008 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
- 30 Nov 2000 New profile
- 29 Nov 2000 Preclinical development for Thrombosis in USA (Unknown route)